HC Wainwright Cuts Earnings Estimates for X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities researchers at HC Wainwright decreased their FY2024 earnings per share estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.66) for the year, down from their previous estimate of ($0.60). HC Wainwright currently has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.04 EPS.

Separately, Stifel Nicolaus lowered their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday.

X4 Pharmaceuticals Stock Down 1.6 %

Shares of XFOR stock opened at $0.40 on Monday. The firm’s 50 day moving average price is $0.58 and its two-hundred day moving average price is $0.74. X4 Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The company has a quick ratio of 6.04, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 239,436 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $131,689.80. Following the sale, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at $581,742.15. This trade represents a 18.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam S. Mostafa sold 230,645 shares of X4 Pharmaceuticals stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $126,854.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 580,800 shares of company stock worth $321,447. 1.62% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in XFOR. Price T Rowe Associates Inc. MD boosted its stake in X4 Pharmaceuticals by 46.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after buying an additional 12,514 shares in the last quarter. Rhumbline Advisers grew its position in X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after buying an additional 23,831 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of X4 Pharmaceuticals in the third quarter valued at $30,000. XTX Topco Ltd grew its holdings in shares of X4 Pharmaceuticals by 41.7% in the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock worth $106,000 after acquiring an additional 46,397 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of X4 Pharmaceuticals during the third quarter worth $37,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.